{"url_path":"/sec/ewtx/8-k/2026-07-16/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001104659-26-084088-index.html","accession_number":"0001104659-26-084088","cik":"0001710072","ticker":"EWTX","issuer_name":"Edgewise Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001104659-26-084088-index.html","primary_entity_key":"0001710072","primary_entity_name":"Edgewise Therapeutics, Inc."},"word_count":461,"has_tables":true,"body_markdown":"false\n0001710072\n\n0001710072\n\n2026-07-10\n2026-07-10\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\nUNITED STATES\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n**FORM 8-K/A**\n\n**(Amendment No. 1)**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 OR 15(d)\nof The Securities Exchange Act of 1934**\n\n** **\n\n**Date of Report (Date of earliest event\nreported):**\n\n**July 10, 2026**\n\n** **\n\n**Edgewise Therapeutics, Inc.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n**Delaware**\n \n**001-40236**\n \n**82-1725586**\n\n**(State or other jurisdiction**\n\n**of incorporation)**\n\n \n\n \n\n**(Commission File Number)**\n\n \n\n \n**(IRS\nEmployer\nIdentification No.)**\n\n \n\n**1715\n38th St.**\n\n**Boulder****,\nCO****80301**\n\n**(Address of principal executive offices) (Zip Code)**\n\n** **\n\n**(720)****262-7002**** **\n\n**(Registrant’s telephone number, including\narea code)**\n\n** **\n\n**Not Applicable**\n\n**(Former name or former address, if changed since last report)**\n\n** **\n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.\nbelow):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the\nSecurities Act (17 CFR 230.425)\n\n \n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the\nExchange Act (17 CFR 240.14a-12)\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b)\nunder the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c)\nunder the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\n \nTrading\nSymbol(s)\n \nName\nof each exchange on which registered\n\nCommon\nStock, $0.0001 par value per share\n \nEWTX\n \nThe\nNasdaq Global Select Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨\n\n \n\n \n\n** **\n\n \n\n \n\n \n\n**Explanatory Note**\n\n** **\n\nOn July 13,\n2026, Edgewise Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”)\nwith the Securities and Exchange Commission to report, among other things, the completion of the acquisition of the Company’s\nsevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program by Servier\nPharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”, and such transaction, the “Transaction”),\npursuant to the terms and conditions of the previously announced Asset Purchase Agreement by and among the Company and the Buyers.\n\n \n\nThis Current Report on Form 8-K/A is being filed solely to\namend the Initial Report to include the pro forma financial information required by Item 9.01(b) of Form 8-K. This Current Report\non Form 8-K/A should be read in conjunction with the Initial Report, which provides a more complete description of the Transaction."}